Clinical Trials Logo

Clinical Trial Summary

Despite its commonplace use in respiratory medicine the mechanism whereby inhalation challenge with a variety of mild acid aerosols produces a dose related and predictable cough is unknown. In this proposal the investigators wish to use established cough challenge methodology to explore the mechanism of action of agents provoking cough both in health and disease.

The hypotheses to be tested include:

- Intracellular changes in pH, rather than extracellular changes, are key in the activation of TRP receptors, the main sensor for provoking cough.

- ATP acting through P2X channels is the mechanism of increased nerve excitability underlying cough hypersensitivity.


Clinical Trial Description

The investigators have previously demonstrated that mild acids, such as citric, tartaric or phosphoric acid produce a highly reliable cough challenge and that the sensitivity of these are complex individual acids correlates within the population studied inferring a common mechanism of action.In contrast there is no correlation with the other common cough challenge methodology, capsaicin inferring that there are at least two different mechanisms for producing cough with aerosols in man.

Over the past 10 years it has been established that capsaicin works by a specific irritant receptor known as the TRPV1. A second receptor, TRPA1 has been recently discovered and we were the first group to demonstrate that inhalation of agonists of this receptor in the form of the extract of cinnamon (cinnamaldehyde) produces cough in man . TRPA1 is a very attractive candidate for the main cough receptor since it is activated by many common irritants, such as smoke, perfumes and other strong smells known to provoke coughing in patients.

The investigators have cloned the human TRP receptors and expressed them in cell lines. This in vitro work has allowed us to investigate the molecular action of the TRP receptors. Recently, the investigators and others have shown that weak acids can activate TRPA1, not as previously thought by stimulating the external surface of the cells but by altering the intracellular pH. This would explain why weak and not strong acids are better at producing cough, since weaker acids (technically those with a higher pKa) exist in solution in a form which is able to cross the cell membrane and render a change in the intracellular pH, which in turn activates TRPA1 from inside the cell.

In the first study the investigators wish to the simply alter the pH of the nebulised solution provoking cough by altering the balance of the salts in the solution, and then carry out standard cough challenge protocols.

In a second study the investigators wish to examine the effect of a number of known agonists of TRPA1 which are commonly used in the perfumes and foodstuffs in order to understand the rank order of potency of these compounds as tussive agents. This can then be compared to the rank order of potency of the same compounds in causing intracellular pH change in in vitro cell culture systems, in order to test the strength of the hypothesis over a variety of different agonists.

Finally, recent work has shown that blockade of a neuronal ion channel known as P2X3 can dramatically reduce cough. P2X3 responds to the substance adenosine triphosphate (ATP), which has previously been used as a cough challenge solution in man. If the hypothesis that the cough hypersensitivity seen in patients is due to activation of P2X3 is correct then patients will cough at much lower doses of ATP than normal volunteers. We wish to assess the value of ATP, and the related substance AMP and adenosine in a cough challenge protocol. Studying the cough produced by these naturally occurring compounds may allow us to distinguish patients with cough hypersensitivity from those with cough due to other causes, and also lead to a methodology important in future drug development

The greater understanding of the cough reflex which these studies would yield would have important clinical applications pointing the way to novel therapeutic avenues, as well as enhancing our fundamental understanding of the genesis of cough. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02039999
Study type Interventional
Source Hull and East Yorkshire Hospitals NHS Trust
Contact
Status Completed
Phase N/A
Start date February 2015
Completion date August 2016

See also
  Status Clinical Trial Phase
Completed NCT00116337 - Spinal Cord Stimulation to Restore Cough N/A
Not yet recruiting NCT04064333 - Slow-Stream Expiratory Muscle Strength Training for Veterans With Dysphagia Living in Long-term Care N/A
Recruiting NCT02482818 - Efficacy of Pregabalin on Chronic Cough Phase 1/Phase 2
Terminated NCT02269761 - Chest Ultrasound of ER Patients With Cough or SOB
Active, not recruiting NCT02065440 - The Effect of Ebastine/Pseudoephedrine on Subacute Cough N/A
Completed NCT01071161 - The Effect of Azithromycin in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Productive Cough Phase 3
Terminated NCT00668317 - Bronchial Hyper-responsiveness in Reflux Cough Phase 3
Completed NCT00353951 - An Observational Study of Cough / Lower Respiratory Tract Infection (LRTI) in Primary Care N/A
Completed NCT00127686 - Effect of Honey and Dextromethorphan on Nocturnal Cough and Sleep Phase 1
Completed NCT00287339 - The Utility of Nexium in Chronic Cough and Reflux Disease Phase 4
Recruiting NCT05115097 - AI Evaluation of COVID-19 Sounds (AI-EChOS)
Recruiting NCT04457011 - Efficacy and Safety of Susu Zhike Granules for Treating Acute Cough Due to Common Cold With Cold-cough Syndrome in Children Phase 2
Recruiting NCT05042063 - Acoustic Cough Monitoring for the Management of Patients With Known Respiratory Disease
Recruiting NCT03922373 - A Study of Benzonatate Soft Capsule in Chinese Healthy Subjects Phase 1
Completed NCT05812209 - Stellate Ganglion Block to Treat Long COVID 19 Case Series
Recruiting NCT04767074 - A Non-pharmacological Cough Control Therapy N/A
Recruiting NCT05570539 - Assessment of the Pharmacokinetics of BLU-5937 Extended Release Prototypes and a BLU-5937 Immediate Release Reference Formulation Phase 1
Completed NCT03999203 - A Cross-sectional Study to Measure Cough in Severe Asthma N/A
Active, not recruiting NCT05479929 - Work of Breathing Assessment in Triage Scale
Recruiting NCT02495571 - Assessment of Voluntary and Reflex Cough in Patients With ALS N/A